Pancreas · 2010 · 26 citations · 28 references
MedicineOncologyPharmacologyApoptosisMolecular OncologyMolecular PharmacologyApoptosis PharmacologyApoptosis ResistanceBcl-2 Family ProteinsCytotoxic ChemotherapyPancreatic CancerAnti-apoptotic Bcl-2 Protein InhibitionBcl-2 InhibitionBcl2 InhibitionGemcitabine-based TherapyIn Vivo Efficacy TestingMcl-1 FunctionPancreatic Cancer PharmacotherapyRegulation By Bcl-2 Family Proteins
OBJECTIVE: Overexpression of antiapoptotic Bcl-2 family proteins confers resistance to conventional therapy in pancreatic cancer patients. Apogossypolone (ApoG2) is an analogue of (-)-gossypol, exhibiting binding activity with Ki values of 35 nmol/L for Bcl-2 and 25 nmol/L for Mcl-1. The present study was designed to test our hypothesis whether inactivation of Bcl-2 family of proteins using ApoG2 could sensitize pancreatic cancer cells to the cytotoxic effect of gemcitabine. METHODS: Two pancreatic cancer cell lines were treated with ApoG2, gemcitabine, and their combination; cytotoxicity and apoptosis was confirmed by MTT and histone/DNA enzyme-linked immunosorbent assay. Coimmunoprecipitation experiments were performed to elucidate the mechanism of action of ApoG2. In vivo efficacy of ApoG2 was evaluated in a xenograft model to confirm its therapeutic benefit with gemcitabine. RESULTS: When ApoG2 was combined with gemcitabine, increased cytotoxicity and apoptosis was evident. Coimmunoprecipitation experiment revealed that ApoG2 blocks the heterodimerization of Mcl-1/Bax and Bcl-2/Bim in cells. Furthermore, administration of ApoG2 with gemcitabine resulted in a statistically higher antitumor activity compared with either ApoG2 or gemcitabine alone in a severe combined immunodeficiency mouse xenograft model. CONCLUSIONS: Apogossypolone, which functions as a potent pan-Bcl-2 family inhibitor, seems therapeutically promising for future translational studies including the treatment of pancreatic cancer.
28
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2009 · 9.7K citations · Full text
Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
Michael C. Wei, Wei‐Xing Zong, Emily H. Cheng et al. · Science · 2001 · 3.9K citations · Full text
Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.9K citations
Medicine, Oncology, Pharmacology +17
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations
The Pathophysiology of Mitochondrial Cell Death
Douglas R. Green, Guido Kroemer · Science · 2004 · 3.4K citations